Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.90 | 07:00:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.90 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.78 - 8.8465 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.90 | USD |
Aprea Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 22.05M | 3.74M | - | 583k | -14.29M | -3.82 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aprea Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.08 | 6.31 | 5.6901 | 5.96 | 6,152 | -0.18 | -2.96% |
| 1 Month | 6.57 | 6.8799 | 5.6901 | 6.31 | 12,450 | -0.67 | -10.20% |
| 3 Months | 5.72 | 8.8465 | 4.8201 | 6.61 | 35,883 | 0.18 | 3.15% |
| 6 Months | 5.49 | 8.8465 | 3.35 | 6.08 | 22,483 | 0.41 | 7.47% |
| 1 Year | 4.03 | 8.8465 | 2.78 | 4.69 | 26,214 | 1.87 | 46.40% |
| 3 Years | 85.80 | 156.00 | 2.78 | 80.08 | 627,120 | -79.90 | -93.12% |
| 5 Years | 309.20 | 1,062.20 | 2.78 | 118.72 | 565,736 | -303.30 | -98.09% |
Aprea Therapeutics Description
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |
